1927857-61-1

Basic information

• Product Name: PQR530
• Synonyms: PQR530
• CAS NO: 1927857-61-1
• Molecular Formula: C18H23F2N7O2
• Molecular Weight: 407.42
• EINECS: -0
• Mol File: 1927857-61-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 660.7±65.0 °C(Predicted)
• Appearance: /
• Density: 1.338±0.06 g/cm3(Predicted)
• PKA: 5.05±0.10(Predicted)
• CAS DataBase Reference: PQR530(CAS DataBase Reference)
• NIST Chemistry Reference: PQR530(1927857-61-1)
• EPA Substance Registry System: PQR530(1927857-61-1)

Safety Data

• Hazardous Substances Data: 1927857-61-1(Hazardous Substances Data)

Usage

Description

PQR530 is a versatile chemical compound that serves as a foaming agent in various industrial applications. It is recognized for its halogen-free, non-toxic, and environmentally friendly properties, making it an ideal alternative to traditional foaming agents. With high stability and compatibility with a broad spectrum of chemicals, PQR530 is a safe and effective ingredient for numerous formulations.

Uses

Used in Cleaning Products Industry:
PQR530 is used as a foaming agent for enhancing the cleaning capabilities of products. Its high stability and compatibility with other chemicals make it an effective ingredient in formulations for various cleaning solutions.
Used in Fire Extinguisher Industry:
PQR530 is utilized as a foaming agent in fire extinguishers to help suppress and extinguish fires. Its non-toxic and environmentally friendly nature ensures safety for both users and the environment during fire emergencies.
Used in Insulation Materials Industry:
PQR530 is employed as a foaming agent in the production of insulation materials to improve their thermal insulation properties. Its low toxicity and reactivity contribute to the safety and eco-friendliness of these materials.

Upstream product

• 6601-22-5 2,6-Dichloro-4-morpholino-1,3,5-triazine 
• 74572-04-6 (3R)-3-methylmorpholine 
• 1204296-03-6 2-chloro-4-(difluoromethyl)pyridine 
• 350595-57-2 (S)-3-methylmorpholine 
• 1197160-99-8 2-chloro-4-[(3S)-3-methylmorpholin-4-yl]-6-(morpholin-4-yl)-1,3,5-triazine 

Relevant articles and documents

4-(Difluoromethyl)-5-(4-((3 R,5 S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders

The mechanistic target of rapamycin (mTOR) pathway is hyperactivated in cancer and neurological disorders. Rapalogs and mTOR kinase inhibitors (TORKi) have recently been applied to alleviate epileptic seizures in tuberous sclerosis complex (TSC). Herein, we describe a pharmacophore exploration to identify a highly potent, selective, brain penetrant TORKi. An extensive investigation of the morpholine ring engaging the mTOR solvent exposed region led to the discovery of PQR626 (8). 8 displayed excellent brain penetration and was well-tolerated in mice. In mice with a conditionally inactivated Tsc1 gene in glia, 8 significantly reduced the loss of Tsc1-induced mortality at 50 mg/kg p.o. twice a day. 8 overcomes the metabolic liabilities of PQR620 (52), the first-in-class brain penetrant TORKi showing efficacy in a TSC mouse model. The improved stability in human hepatocytes, excellent brain penetration, and efficacy in Tsc1GFAPCKO mice qualify 8 as a potential therapeutic candidate for the treatment of neurological disorders.

TREATMENT OF SKIN DISORDERS

The present invention relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(0)0-C1- C2alkyl; or R3 and R4 form together a bivalent residue -R5R6- selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-0-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1- C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue -R8R9- selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-0-CH2- or -0- CH2CH2-0-; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in a method of treating a skin disorder in a subject, wherein said skin disorder is a genodermatosis, a vascular anomaly or a skin disorder selected from scleroderma, sclerodermatous chronic graft-versus-host disease, lichen sclerosus, lichen planus, lichen ruber planus and scars.

TREATMENT OF SKIN LESIONS

The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1 X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1alkoxyC1-C3alkyl, CN, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue -R5R6- selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue-R8R9- selected from Ci-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CH2CH2-O-; with the proviso that at least one of R1 and R2is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a skin lesion in a subject.